AVL

2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one

Created:2012-08-28
Last modified:  2013-10-02

Find related ligands:

Chemical Details

Formal Charge0
Atom Count35
Chiral Atom Count0
Bond Count36
Aromatic Bond Count10
2D diagram of AVL

Chemical Component Summary

Name2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one
Systematic Name (OpenEye OEToolkits)2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
FormulaC14 H18 N2 O
Molecular Weight230.306
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01O=C(c1c2ccccn2nc1C(C)C)C(C)C
SMILESCACTVS3.370CC(C)C(=O)c1c2ccccn2nc1C(C)C
SMILESOpenEye OEToolkits1.7.6CC(C)c1c(c2ccccn2n1)C(=O)C(C)C
Canonical SMILESCACTVS3.370 CC(C)C(=O)c1c2ccccn2nc1C(C)C
Canonical SMILESOpenEye OEToolkits1.7.6 CC(C)c1c(c2ccccn2n1)C(=O)C(C)C
InChIInChI1.03 InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
InChIKeyInChI1.03 ZJVFLBOZORBYFE-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB05266 
NameIbudilast
Groups investigational
DescriptionIbudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.
Synonyms
  • Ibudilast
  • Ibudilastum
IndicationFor the treatment of multiple sclerosis, asthma, and cerebrovascular disease.
Categories
  • Anti-Asthmatic Agents
  • Antiplatelet agents
  • Autonomic Agents
  • Bronchodilator Agents
  • Cardiovascular Agents
ATC-CodeR03DC04
CAS number50847-11-5

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
3',5'-cyclic-AMP phosphodiesterase 4AMEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSD...unknowninhibitor
3',5'-cyclic-AMP phosphodiesterase 4BMKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL...unknowninhibitor
3',5'-cyclic-AMP phosphodiesterase 4CMENLGVGEGAEACSRLSRSRGRHSMTRAPKHLWRQPRRPIRIQQRFYSDP...unknowninhibitor
3',5'-cyclic-AMP phosphodiesterase 4DMEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRL...unknowninhibitor
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3AMAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDL...unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL19449
PubChem 3671
ChEMBL CHEMBL19449
ChEBI CHEBI:31684